- Medical device company Creo Medical Group said it had received its first commercial orders for a range of gastrointestinal devices.

The so-called Speedboat device was the first of the range to be cleared for use.

It combined bipolar radiofrequency energy for precise tissue dissection. along with microwave energy for highly controlled coagulation and tissue ablation.

The first purchase orders came from two US hospitals and followed on from a successful roll out of the company's Clinical Education Programme in the US, which had now trained seven GI Endoscopists across six hospitals.

At 2:55pm: [LON:CREO] Creo Medical Group Plc share price was +18p at 185p

Story provided by